Why Lenz picked a reverse merger instead of an IPO: Q&A

22 Mar 2024
endpts.com
IPOAcquisitionPhase 3
Following Lenz Therapeutics’ debut on the Nasdaq Friday, Endpoints News spoke with CEO Eef Schimmelpennink about the thinking behind choosing a reverse merger over an IPO and its upcoming Phase 3 results.
In the next few weeks, Lenz is expected to report data from Phase 3 studies of its eye drops LNZ100 and LNZ101. It then plans to pick the better of the two to submit for approval as it plans to go up against AbbVie’s Vuity and Orasis Pharmaceuticals’ Qlosi, which was approved last October.
Why Lenz picked a reverse merger instead of an IPO: Q&A
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.